Torsade de pointes induced by cisapride/clarithromycin interaction

被引:63
作者
Piquette, RK [1 ]
机构
[1] Ottawa Civic Hosp, Dept Pharmaceut Serv, Ottawa, ON K1Y 4E9, Canada
关键词
cisapride; clarithromycin; cytochrome P450 enzymes; torsade de pointes;
D O I
10.1345/aph.18107
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: TO highlight a case of torsade de pointes ventricular arrhythmia induced by the concomitant use of cisapride and clarithromycin. CASE SUMMARY: A 77-year-old white woman was admitted to the hospital with a diagnosis of pneumonia and exacerbation of congestive heart failure. In addition to her usual medications, which included cisapride, the patient was prescribed trimethoprim/sulfamethoxazole and clarithromycin for pneumonia. Within 48 hours, the patient had documented episodes of symptomatic torsade de pointes arrhythmia, which eventually responded to therapy. Both cisapride and clarithromycin were discontinued, and the patient did not have any recurring episodes during a 32-month follow-up. DISCUSSION: Cisapride has been implicated in causing adverse cardiac events, including torsade de pointes,arrhythmia. In most cases, the patients had preexisting risk factors for torsade de pointes and/or were receiving other medications known to inhibit the hepatic CYP3A4 enzyme system and the metabolism of cisapride. There is evidence that clarithromycin, a relatively new macrolide antibiotic, also inhibits the isoenzyme CYP3A4. The resulting accumulation of cisapride caused by concomitant clarithromycin therapy was believed to have been the cause of the torsade de pointes arrhythmia in this patient. CONCLUSIONS: Concomitant use of cisapride and clarithromycin may cause torsade de pointes arrhythmia.
引用
收藏
页码:22 / 26
页数:5
相关论文
共 34 条
[11]   COMPARISON OF THE EFFECT OF THE MACROLIDE ANTIBIOTICS ERYTHROMYCIN, CLARITHROMYCIN AND AZITHROMYCIN ON TERFENADINE STEADY-STATE PHARMACOKINETICS AND ELECTROCARDIOGRAPHIC PARAMETERS [J].
HONIG, PK ;
WORTHAM, DC ;
ZAMANI, K ;
CANTILENA, LR .
DRUG INVESTIGATION, 1994, 7 (03) :148-156
[12]   TERFENADINE-KETOCONAZOLE INTERACTION - PHARMACOKINETIC AND ELECTROCARDIOGRAPHIC CONSEQUENCES [J].
HONIG, PK ;
WORTHAM, DC ;
ZAMANI, K ;
CONNER, DP ;
MULLIN, JC ;
CANTILENA, LR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (12) :1513-1518
[13]  
HUMPHREY PPA, 1992, BRIT MED J, V304, P1019
[14]  
INMAN W, 1992, BRIT MED J, V305, P1019, DOI 10.1136/bmj.305.6860.1019-a
[15]  
*JANSS PHARM, 1989, PROD INF CIS PREP
[16]  
Lai D, 1996, CAN J HOSP PHARM, V49, P33
[17]   Sex difference in risk of torsade de pointes with d,l-sotalol [J].
Lehmann, MH ;
Hardy, S ;
Archibald, D ;
Quart, B ;
MacNeil, DJ .
CIRCULATION, 1996, 94 (10) :2535-2541
[18]   QT PROLONGATION AND TORSADES-DE-POINTES AFTER ADMINISTRATION OF TRIMETHOPRIM-SULFAMETHOXAZOLE [J].
LOPEZ, JA ;
HAROLD, JG ;
ROSENTHAL, MC ;
OSERAN, DS ;
SCHAPIRA, JN ;
PETER, T .
AMERICAN JOURNAL OF CARDIOLOGY, 1987, 59 (04) :376-377
[19]   PROBABLE TERFENADINE-FLUOXETINE-ASSOCIATED CARDIAC TOXICITY [J].
MARCHIANDO, RJ ;
COOK, MD ;
JUE, SG .
ANNALS OF PHARMACOTHERAPY, 1995, 29 (09) :937-938
[20]   TORSADE-DE-POINTES - MECHANISMS AND MANAGEMENT [J].
NAPOLITANO, C ;
PRIORI, SG ;
SCHWARTZ, PJ .
DRUGS, 1994, 47 (01) :51-65